MoneyWorks4Me

Zydus Lifesciences informs about press release

14 Mar 2024 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated March 14, 2024 titled ‘Zydus receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1134.20 -15.80 (-1.37%)
09-Sep-2026 11:43 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1876.90
Dr. Reddys Labs. 1143.00
Cipla 1373.00
Lupin 2100.90
Zydus Lifesciences 1134.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: